Rep. Lloyd Doggett (D-TX) Buys Johnson & Johnson (JNJ) Stock
House Democrat Lloyd Doggett buys between $1,001 and $15,000 of Johnson & Johnson shares.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rep. Lloyd Doggett (D-TX) bought between $1,001 and $15,000 of Johnson & Johnson ($JNJ) stock on September 8, 2026. The trade was disclosed in a STOCK Act periodic transaction report filed October 5, 2026.
Since the trade, $JNJ is down 0.7% after 1 week, down 4.7% after 1 month and down 5.0% to date (from the $269.12 close on Sep 8, 2026).
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Lloyd Doggett (D-TX)
- Status:
- Member — House
- State/District:
- TX-37
- Party:
- Democrat
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Oct 5, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Johnson & Johnson ($JNJ) | Buy | Sep 8, 2026 | $1,001 - $15,000 |
Summary of the filed report, not the original document. View the original: STOCK Act disclosure (House Clerk)
JNJ
Johnson & Johnson
Key Points
- Lloyd Doggett, a Democrat in the House, purchased Johnson & Johnson stock valued between $1,001 and $15,000 as disclosed on October 5, 2026.
- Johnson & Johnson, trading on NYSE under JNJ, has a market cap of $649.4 billion and a P/E ratio of 31.3.
- The company operates in healthcare, with segments in Innovative Medicine and MedTech, and offers a dividend yield of 1.99%.
Get $JNJ trade alerts by text
We text you when insiders, Congress or big funds trade $JNJ. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Johnson & Johnson alert may contain errors. Disclosures
Lloyd Doggett, a Democrat representing Texas' 37th district in the U.S. House of Representatives, recently made a purchase of Johnson & Johnson stock. The transaction, valued between $1,001 and $15,000, was disclosed on October 5, 2026, as part of the STOCK Act requirements for congressional financial transparency.
Lloyd Doggett vs. the S&P 500
Hypothetical returns from Lloyd Doggett's disclosed trades, not real profit or advice. How we model this.
Johnson & Johnson Stock Up 0.6%
Shares of NYSE:JNJ traded near $100 on Friday. Johnson & Johnson, a major player in the healthcare sector, boasts a market cap of approximately $649.4 billion. The company has a P/E ratio of 31.3 and a forward P/E of 22.2, indicating investor expectations for future earnings growth. With a beta of 0.235, the stock is less volatile compared to the overall market. Over the past year, its shares have ranged from $174.83 to $281.07, with a 50-day moving average of $263.54 and a 200-day moving average of $238.98.
Recent Earnings
Johnson & Johnson reported revenue of about $97.9 billion, reflecting a revenue growth of 6.6%. The company achieved a net margin of 21.5% and a return on equity of 25.7%. Its earnings per share stood at $8.61. Investors are looking forward to the next earnings report scheduled for October 13, 2026.
Dividend
The company pays an annual dividend of $5.36 per share, yielding 1.99%. Its dividend payout ratio is 60.8%, indicating a balanced approach to rewarding shareholders while retaining earnings for growth. The ex-dividend date wasn't specified in the recent data.
About Johnson & Johnson
Johnson & Johnson is a global healthcare company based in New Brunswick, New Jersey. It focuses on research, development, and sales of a wide range of healthcare products. The company operates through two main segments: Innovative Medicine, which covers areas like oncology and immunology, and MedTech, which includes surgical and orthopedic products. Led by CEO Joaquin Duato, Johnson & Johnson employs over 138,000 people worldwide.
Bottom Line
Lloyd Doggett's investment in Johnson & Johnson underscores the interest in this healthcare giant. The company's strong market position and financial metrics, such as a solid P/E ratio and steady dividend yield, continue to attract investors. As with all 13F and STOCK Act filings, this disclosure reflects past activity and may not indicate current holdings.
Related Filing Alerts
Source: Lloyd Doggett's STOCK Act disclosure on $JNJ (Sep 8, 2026). Read the original filing: STOCK Act disclosure (House Clerk). Written by software, not financial advice. How we make alerts